retatrutide clinical trials dosage Reta trial data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 for metabolic health — targeting GLP-1, GIP How Retatrutide Dosing Is Studied

Join Our Waitlist Now Retatrutide is expected to receive FDA approval in 2027

The native GLP-1 peptide provides the most direct tool for interrogating all of these receptor-mediated pathways at source, without the confounding structural modifications present in GLP-1RA drug compounds

staggered titration Cycle driver GI tolerance sets the pace Retatrutide Loading 2 mg 4 mg 8 mg (weeks 1-12) Frequency Once weekly Maintenance 12 mg weekly Route SubQ Cagrilintide Loading Start Week 9: 0.25 0.5 1.0 1.7 mg Frequency Once weekly Maintenance 2.4 mg weekly Route SubQ Weekly Schedule Example (Maintenance Phase) Monday Retatrutide 12 mg (one site) + Cagrilintide 2.4 mg (different site) Tuesday No injections Wednesday No injections Thursday No injections Friday No injections Saturday No injections Sunday No injections Both compounds are once-weekly

see Figure 2 for a graphical display of the product as a volcano plot

Drinking alcohol increased appetite score in the control group, but not in the GLP-1RA group (Group x Time interaction ( 2 (1) = 5.9106, p = 0.015, f = 0.57